APAC BioSurgery Market

APAC BioSurgery Market Size (2022 to 2027)

The size of the BioSurgery Market in the Asia Pacific was worth USD 4.30 billion in 2022 and is estimated to be growing at a CAGR of 10.43% to reach USD 7.05 billion by 2027 during the forecast period.

Biomaterials are biologically compatible glues used to seal surgical incisions, or lubricants to help joint movement or support structures on which living tissue is grown or shaped. Still, the term also covers biocompatible materials such as hip replacements and artificial pacemakers. It also includes bio-therapeutic techniques such as gene and cellular therapies. All these techniques combined make up the field of bio-surgery.

Biosurgery products help enhance the work efficiency of physicians by controlling surgery-related difficulties inexpensive and complicated surgeries. It utilizes biomaterial, therapeutic, and sophisticated device technologies to improve patients' health in the orthopedic and post-surgery care departments.

The primary factor affecting the Bio Surgery market is the increasing number of surgeries carried out due to changing lifestyles. Additionally, the popularity of sports has led to an increase in the number of spine-related injuries. The rise in the geriatric population is the primary driver of the market in the region.

However, the industry is still plagued by the increasing costs of surgeries, the growing demand for minimally invasive techniques, and the stringent government regulations and reimbursement policies, all of which restrain the market growth.

This research report on the Asia Pacific BioSurgery Market has been segmented and sub-segmented into the following categories.

• By Type: Sealants, Haemostatic Agents, Adhesion Barriers, Soft Tissue Attachments, Bone Graft Substitutes, and Staple line Reinforcement Agents
• By Application: Orthopaedic, General, Neurological, Cardiovascular, Reconstructive, Gynaecological, Urological, and thoracic Surgeries.
• By Country: India, China, Japan, South Korea, Australia, New Zealand, Thailand, Malaysia, Vietnam, Philippines, Indonesia, Singapore and Rest of APAC

Geographically, The APAC biosurgery market is projected to witness a high CAGE during the analysis period due to the growing prevalence of chronic diseases. Additionally, rising per capita income tends to upgrade the living standards, the ever-increasing amount spent on healthcare, and increasing awareness among the people associated with the biosurgery market in this region.

The Chinese biosurgery market is estimated to lead the market in this region during the analysis period due to rising chronic disorders, increasing chronic diseases such as cardiac disorders and renal disorders. Also, valuable and beneficial measures taken for blood loss during surgeries are likely to augment these methods' obtainment over the forecasting framework.

The biosurgery market in India is anticipated to grow at the fastest rate in this region during the forecast period due to the rapid urbanization, massive population base, and rise in middle-class population with significant discretionary expenses and awareness about the advanced surgical processes are predicted to accelerate the growth of this country in this region.

Companies like Baxter International, C.R. Bard, Johnson & Johnson, Covidien PLC, Getinge Group, B. Braun Melsungen AG, Cryolife Inc., Stryker Corporation, Hemostasis LLC., and Sanofi Group are playing a leading role in the Asia Pacific BioSurgery Market.